PE20131035A1 - Formulacion de nevirapina de liberacion prolongada - Google Patents

Formulacion de nevirapina de liberacion prolongada

Info

Publication number
PE20131035A1
PE20131035A1 PE2013000070A PE2013000070A PE20131035A1 PE 20131035 A1 PE20131035 A1 PE 20131035A1 PE 2013000070 A PE2013000070 A PE 2013000070A PE 2013000070 A PE2013000070 A PE 2013000070A PE 20131035 A1 PE20131035 A1 PE 20131035A1
Authority
PE
Peru
Prior art keywords
nevirapin
formulation
prolonged release
anhydra
nevirapine
Prior art date
Application number
PE2013000070A
Other languages
English (en)
Inventor
Michael Cappola
Svetlana Sienkiewicz
Snow Glenn Charles
Feng-Jing Chen
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39739795&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20131035(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of PE20131035A1 publication Critical patent/PE20131035A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Abstract

REFERIDA A UNA FORMA DE DOSIFICACION FARMACEUTICA EN COMPRIMIDOS QUE COMPRENDE: a) 400 MG DE NEVIRAPINA ANHIDRA, b) 270 MG DE HIPROMELOSA, c) 400 MG DE MONOHIDRATO DE LACTOSA Y d) 10 MG DE ESTEARATO DE MAGNESIO
PE2013000070A 2007-06-08 2008-06-06 Formulacion de nevirapina de liberacion prolongada PE20131035A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US94276507P 2007-06-08 2007-06-08

Publications (1)

Publication Number Publication Date
PE20131035A1 true PE20131035A1 (es) 2013-10-01

Family

ID=39739795

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2013000070A PE20131035A1 (es) 2007-06-08 2008-06-06 Formulacion de nevirapina de liberacion prolongada
PE2008000969A PE20090371A1 (es) 2007-06-08 2008-06-06 Formulacion de nevirapina de liberacion prolongada

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2008000969A PE20090371A1 (es) 2007-06-08 2008-06-06 Formulacion de nevirapina de liberacion prolongada

Country Status (29)

Country Link
US (1) US8460704B2 (es)
EP (1) EP2155169B1 (es)
JP (1) JP5417662B2 (es)
KR (1) KR101017862B1 (es)
CN (1) CN101784263B (es)
AR (1) AR066924A1 (es)
AU (1) AU2008262031B2 (es)
BR (1) BRPI0811732A2 (es)
CA (1) CA2687491C (es)
CL (1) CL2008001678A1 (es)
CO (1) CO6150128A2 (es)
DK (1) DK2155169T3 (es)
EA (1) EA018377B1 (es)
EC (1) ECSP099561A (es)
ES (1) ES2574836T3 (es)
HK (1) HK1145806A1 (es)
HU (1) HUE028598T2 (es)
IL (1) IL199924A0 (es)
MA (1) MA31430B1 (es)
MX (1) MX2009007764A (es)
NZ (1) NZ578664A (es)
PE (2) PE20131035A1 (es)
PL (1) PL2155169T3 (es)
TN (1) TN2009000510A1 (es)
TW (1) TWI419716B (es)
UA (1) UA97971C2 (es)
UY (1) UY31128A1 (es)
WO (1) WO2008154234A2 (es)
ZA (1) ZA200904939B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
US20130172274A1 (en) 2005-12-20 2013-07-04 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
CN101784263B (zh) 2007-06-08 2012-11-07 贝林格尔.英格海姆国际有限公司 奈韦拉平的延长释放制剂
EP4074327A1 (en) 2008-06-27 2022-10-19 Duke University Therapeutic agents comprising elastin-like peptides
CA2835272A1 (en) 2011-05-30 2012-12-06 Cipla Limited Pharmaceutical antiretroviral composition
EP4295858A1 (en) * 2011-08-24 2023-12-27 ImmunoForge Co., Ltd. Formulations of active agents for sustained release
EP2822560A1 (en) * 2012-03-05 2015-01-14 Cipla Limited Pharmaceutical antiretroviral combinations comprising lamivudine, festinavir and nevirapine
CN104523630B (zh) * 2015-01-22 2017-08-25 山东新时代药业有限公司 一种奈韦拉平片剂
EP3153157A1 (en) 2015-10-09 2017-04-12 Teva Pharmaceutical Works Private Limited Company Pharmaceutical composition for prolonged release of nevirapine

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5366972A (en) 1989-04-20 1994-11-22 Boehringer Ingelheim Pharmaceuticals, Inc. 5,11-dihydro-6H-dipyrido(3,2-B:2',3'-E)(1,4)diazepines and their use in the prevention or treatment of HIV infection
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
CA2030056C (en) 1989-11-17 1995-10-17 Karl D. Hargrave 5,11-dihydro-6h-dipyrido[3,2-b:2',3'-e][1,4]diazepines and their use in the prevention or treatment of hiv infection
US5419917A (en) * 1994-02-14 1995-05-30 Andrx Pharmaceuticals, Inc. Controlled release hydrogel formulation
US6514530B2 (en) * 1997-09-09 2003-02-04 Alza Corporation Dosage form comprising means for changing drug delivery shape
DE69805001T2 (de) 1997-12-05 2002-08-22 Alza Corp Osmotische darreichungsform mit zwei mantelschichten
PT1140012E (pt) * 1998-12-17 2004-05-31 Alza Corp Conversao de capsulas de gelatina cheias com liquido em sistemas de libertacao controlada por camadas multiplas
MX339071B (es) * 1999-03-31 2016-05-09 Janssen Pharmaceutica Nv Almidon pregelatinizado en una formulacion de liberacion controlada.
OA12029A (en) * 1999-09-24 2006-04-28 Janssen Pharmaceutica Nv Antiviral compositions.
EP1239840B1 (en) 1999-12-09 2005-04-06 Alza Corporation Antiviral medication
US6541014B2 (en) 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
WO2002092095A1 (en) 2001-05-11 2002-11-21 Boehringer Ingelheim International Gmbh Use of nevirapine to treat or prevent lipid pathology in patients with hiv that is resistant to nevirapine
US20030050620A1 (en) 2001-09-07 2003-03-13 Isa Odidi Combinatorial type controlled release drug delivery device
WO2004043435A2 (en) 2002-11-13 2004-05-27 Control Delivery Systems, Inc. Systemic delivery of antiviral agents
US20070259014A1 (en) 2003-06-20 2007-11-08 Vgx Pharmaceuticals, Inc. Compositions for and Methods for Treating Hiv
EP1673072B1 (en) 2003-10-01 2007-04-04 Lupin Limited A controlled release pharmaceutical composition and a process for preparing the same
NZ581461A (en) 2003-11-13 2011-04-29 Psivida Inc Injectable sustained release delivery devices
KR101284361B1 (ko) * 2004-09-02 2013-07-15 얀센 파마슈티카 엔.브이. 4-((4-((4-(2-시아노에텐일)-2,6-디메틸페닐)아미노-2-피리미딘일)아미노)벤조니트릴의 하이드로클로라이드
WO2006114709A1 (en) * 2005-04-25 2006-11-02 Aurobindo Pharma Limited Pharmaceutical compositions of antiretrovirals
AU2006263338A1 (en) 2005-06-29 2007-01-04 Panacea Biotec Ltd. Pharmaceutical sustained release compositions and processes thereof
EP1906937B1 (en) 2005-07-22 2016-10-19 Rubicon Research Pvt Ltd. Novel dispersible tablet composition
FR2891459B1 (fr) 2005-09-30 2007-12-28 Flamel Technologies Sa Microparticules a liberation modifiee d'au moins un principe actif et forme galenique orale en comprenant
WO2007047371A2 (en) * 2005-10-14 2007-04-26 Microdose Technologies, Inc. Pharmaceutical packaging of an oral dosage combination
CN101784263B (zh) 2007-06-08 2012-11-07 贝林格尔.英格海姆国际有限公司 奈韦拉平的延长释放制剂

Also Published As

Publication number Publication date
TN2009000510A1 (en) 2011-03-31
AU2008262031A1 (en) 2008-12-18
ZA200904939B (en) 2010-04-28
NZ578664A (en) 2011-11-25
KR101017862B1 (ko) 2011-03-04
EA200900958A1 (ru) 2010-04-30
JP5417662B2 (ja) 2014-02-19
ES2574836T3 (es) 2016-06-22
CN101784263A (zh) 2010-07-21
TW200916127A (en) 2009-04-16
BRPI0811732A2 (pt) 2014-11-18
PE20090371A1 (es) 2009-04-24
AU2008262031B2 (en) 2011-08-25
WO2008154234A2 (en) 2008-12-18
CL2008001678A1 (es) 2009-09-11
KR20100020447A (ko) 2010-02-22
EA018377B1 (ru) 2013-07-30
US20100278918A1 (en) 2010-11-04
AR066924A1 (es) 2009-09-23
UA97971C2 (ru) 2012-04-10
US8460704B2 (en) 2013-06-11
EP2155169A2 (en) 2010-02-24
CN101784263B (zh) 2012-11-07
PL2155169T3 (pl) 2016-09-30
CA2687491C (en) 2011-09-20
EP2155169B1 (en) 2016-03-23
WO2008154234A9 (en) 2009-11-26
CO6150128A2 (es) 2010-04-20
DK2155169T3 (en) 2016-06-13
WO2008154234A3 (en) 2010-01-21
TWI419716B (zh) 2013-12-21
UY31128A1 (es) 2009-01-30
ECSP099561A (es) 2009-09-29
HUE028598T2 (en) 2016-12-28
CA2687491A1 (en) 2008-12-18
IL199924A0 (en) 2010-04-15
HK1145806A1 (en) 2011-05-06
MX2009007764A (es) 2009-09-10
MA31430B1 (fr) 2010-06-01
JP2010520891A (ja) 2010-06-17

Similar Documents

Publication Publication Date Title
PE20131035A1 (es) Formulacion de nevirapina de liberacion prolongada
CO6440564A2 (es) Composiciones farmacéuticas de liberación inmediata que comprenden oxicodona y naloxona
CR20140340A (es) Formas farmacéuticas de dosificación oral resistente a interferencias que comprenden un analgésico opioide
CL2011001621A1 (es) Composicion farmaceutica oral de liberacion sostenida que comprende en una forma de dosificacion unitaria, una matriz hidrofilica, un opioide, una sal de un aine, y opcionalmente un surfactante aniónico; y uso para preparar medicamentos utiles en la prevencion, alivio o disminución del nivel del dolor y supresión de la tos.
MA29115B1 (fr) Produits pharmaceutiques solides, administres par voie orale et contenant du rivaroxaban, a liberation modifiee
MX2008012731A (es) Tabletas de paracetamol de liberacion rapida.
CO6400186A2 (es) Tabletas de acetato de ulipristal
AR065809A1 (es) Formulaciones farmaceuticas que contienen un inhibidor sglt2
BRPI0615989B8 (pt) formulação farmacêutica de dosagem oral
IL192773A0 (en) Microparticulate pharmaceutical forms resistant to immediate release of the active ingredient in the presence of alcohol
NO20070887L (no) Kornformet farmasoytisk preparat med tidsbegrenset frigivelse for oral administrasjon, og intraoral hurtig desintegrerende tablett som inneholder preparatet
ES2916604T1 (es) Ensayos de detección de nrf2 y métodos y composiciones relacionados
UA116334C2 (uk) Тверді форми дозування бендамустину
CL2013000677A1 (es) Composicion farmaceutica en forma de tabletas que comprenden microgranulos gastrointestinales que contienen 100 a 800 mg de rifaximina, hasta 30% p/p de excipientes extragranulares y un recubrimiento formador de pelicula; y uso para tratar una enfermedad infecciosa y/o inflamatoria del intestino, tal como la enfermedad de crohn.
RS54244B1 (en) NALBUFINE BASED FORMULATIONS AND THEIR USE
AR077284A1 (es) Composiciones de dosis fija farmaceuticas solidas que comprenden irbesartan y amlodipina, su preparacion y su aplicacion terapeutica
AR077546A1 (es) Formulaciones de comprimidos de 3-cianoquinolina y usos de los mismos
IL195931A0 (en) Pharmaceutical preparation for oral administration with controlled active ingredient release in the small intestine and methods for its production
TN2015000135A1 (en) Modified release formulations for oprozomib
CO6150126A2 (es) Formulaciones de comprimidos de liberacion inmediata de un antagonista del receptor de trombina
JO3587B1 (ar) أشكال جرعات بينداموستين عن طريق الفم
CL2013003176A1 (es) Formulacion farmaceutica oral de liberacion sostenida que comprende dos tabletas que contienen 1000 mg de paracetamol, el cual esta presente en una capa de liberacion sostenida y otra de liberacion inmediata, en una proporcion de paracetamol por capa de 80-90 %: 10-20 %, donde la dosis unitaria comprende 2000 mg de paracetamol.
TR201001903A2 (tr) Uzatılmış salımlı tiyokolşiklozit tablet.
AR080256A1 (es) Formulaciones farmaceuticas solidas de ramipril y besilato de amlodipino y su preparacion
MY153610A (en) Fixed dose combination in form of a bilayered or monolayered tablet of aliskiren and amlodipine

Legal Events

Date Code Title Description
FD Application declared void or lapsed